《Molecular Cancer Therapeutics》雜志的最新年發文量為116篇。
這表明該刊在每年都會精選并發表一定數量的高質量文章，以保持其在腫瘤學領域的學術影響力。
該刊聚焦于醫學-腫瘤學領域的前沿研究，致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 約3月 。
Molecular Cancer Therapeutics 雜志發文統計
文章名稱引用次數
- Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes77
- Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes33
- Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer32
- Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer31
- Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies27
- Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)26
- Strategies to Address Chimeric Antigen Receptor Tonic Signaling23
- MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma22
- Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors21
- We're Not DON Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine20
國家/地區發文量
- USA1110
- CHINA MAINLAND137
- England131
- Japan131
- GERMANY (FED REP GER)78
- South Korea66
- Netherlands63
- Italy60
- Canada55
- France55
